Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 2c

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12).

“2018 was a transformational year for Catalyst with the approval of Firdapse® (amifampridine phosphate) tablets, the first and only evidence-based, FDA approved treatment for patients with Lambert-Eaton myasthenic syndrome or LEMS. With this approval, all adult LEMS patients will now have affordable access to Firdapse,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “We are pleased with the robust momentum that we have seen since the launch of Firdapse, including patient enrollment forms, the breadth of prescribers, and positive reimbursement trends. In 2019, we will remain laser-focused on the commercial launch of Firdapse, as well as on our efforts in the clinic to evaluate Firdapse as a potential therapy to treat other rare neuromuscular diseases.”

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery